NIVOLUMAB (Opdivo) prior authorization at Geisinger Health Plan
Submission criteria, P2P prep, and appeal path if denied — for prescribers and PA staff
Geisinger Health Plan requires Programmed Death Receptor-1 Blocking Antibody prior-authorization documentation for NIVOLUMAB (Opdivo): a diagnosis with ICD-10 code, documented step-therapy history, and prescriber attestation of medical necessity. Standard PA decisions return on the clock printed in the current member-specific payer source; if denied, use the appeal window printed on the denial notice to appeal.
The PA criteria you'll need to meet
Geisinger Health Plan reviews NIVOLUMAB (Opdivo) prior authorizations against its medical policy for Programmed Death Receptor-1 Blocking Antibody. Geisinger Health Plan-specific context: Integrated payer-provider system in central/northeast Pennsylvania (~600K members). Acquired by Kaiser-affiliated Risant Health in March 2024 — operational integration ongoing. PA Insurance Department oversight. Strong MA presence in service area.
Documentation packet checklist
- Chart note with diagnosis (ICD-10 code) and clinical severity markers
- Documented failure of, contraindication to, or intolerance of step-therapy alternatives in Programmed Death Receptor-1 Blocking Antibody
- Prior treatment history including dosing, duration, and reason for discontinuation
- Relevant labs, imaging, or assessment scores supporting medical necessity
- Prescriber attestation linking the FDA-approved indication to the patient's presentation
- Geisinger Health Plan's medical policy URL referenced in the cover letter
Denial scenarios to check against the current policy
These are preparation scenarios, not frequency claims. Use only those supported by the current member-specific source:
- Narrow-network denials outside Geisinger system
- Specialty referral coordination
- Medicare Advantage step therapy on Part B drugs
- Out-of-network non-emergency
NIVOLUMAB (Opdivo)-specific review scenarios and context
Check whether the current notice cites any of these label-, REMS-, or policy-related scenarios:
- Off-label indication denial despite NCCN compendium support
- Combination with ipilimumab denied as duplicate therapy
- Adjuvant use denial citing 'no overall survival data'
- Continuation beyond 2 years
Brand: Opdivo. PD-1 inhibitor approved across 20+ indications. Opdualag (nivolumab + relatlimab) is the first LAG-3 combination. Subcutaneous nivolumab (Opdivo Qvantig) FDA-approved December 2024 — appeal denials of subQ formulation citing IV-only preference.
Manufacturer patient-assistance program: BMS Access Support — relevant when a Geisinger Health Plan denial sticks and the patient needs bridge access while appealing.
How Geisinger Health Plan approaches Immune checkpoint inhibitors PAs
For NIVOLUMAB (OPDIVO), check whether the current Geisinger Health Plan Immune checkpoint inhibitors policy cites specialty referral coordination. Pharmacy-benefit review for NIVOLUMAB (OPDIVO) at Geisinger Health Plan is routed through Geisinger Pharmacy (in-house, integrated payer-provider). The applicable review clock depends on the member's current product, whether the request is complete and urgent, and governing plan rules. Confirm receipt and timing with Geisinger Health Plan; if denied, use the filing date and route printed on that denial notice. Off-label oncology appeals at Geisinger Health Plan carry significantly higher reversal rates when the appeal letter cites the specific NCCN compendium evidence-block category (2A or above) rather than peer-reviewed citations alone. Geisinger Health Plan is domiciled in PA, so unresolved appeals escalate to the PA insurance department's external-review program for fully-insured policies (self-funded ERISA plans route to the DOL EBSA instead).
If the PA is denied
Verify the appeal window and decision clock in the current denial notice and member-specific payer source before relying on either. Submit through the provider portal (https://www.geisinger.org/health-plan/providers) with the same packet plus an applicable, current clinical source supporting NIVOLUMAB (Opdivo)for the patient's indication.
Helping a patient appeal the denial directly? See the consumer guide: How to appeal a Geisinger Health Plan denial on DenialHelp.
Contact Geisinger Health Plan
- Provider portal: https://www.geisinger.org/health-plan/providers
Frequently asked questions
What documentation does Geisinger Health Plan need for NIVOLUMAB (Opdivo) prior auth?
Geisinger Health Plan's typical PA packet for NIVOLUMAB (Opdivo): (1) chart note documenting the indication and prior-treatment failures, (2) supporting lab/imaging where indicated, (3) prescriber attestation that step-therapy alternatives were tried or contraindicated, (4) FDA-approved indication mapped to ICD-10 diagnosis. For Programmed Death Receptor-1 Blocking Antibody, expect clinical-criteria documentation specific to this class.
What's the turnaround time at Geisinger Health Plan?
Verify the decision clock in the current member-specific payer policy and request receipt. Product type, urgency, state law, and plan terms can change the applicable timing; this page does not supply an operational deadline.
What documentation issues should be checked for NIVOLUMAB (Opdivo) at Geisinger Health Plan?
Preparation scenarios to check against the current notice and policy include: Narrow-network denials outside Geisinger system; Specialty referral coordination; Medicare Advantage step therapy on Part B drugs. These are not measured frequency claims. For NIVOLUMAB (Opdivo), verify whether the actual denial raises step therapy, indication, or another plan-specific criterion before responding.
Does Geisinger Health Plan cover off-label use of NIVOLUMAB (OPDIVO) supported by NCCN compendium?
Geisinger Health Plan may consult the NCCN Drugs & Biologics Compendium for oncology coverage. For off-label NIVOLUMAB (OPDIVO), cite the current compendium entry by version and table, name the evidence-block category, and attach the supporting clinical-trial or meta-analysis reference. Verify the member-specific coverage rule and timing before relying on this preparation guide. Pharmacy-benefit handling is routed through Geisinger Pharmacy (in-house, integrated payer-provider). External-review escalation for Geisinger Health Plan fully-insured policies sits with the PA insurance department.
How do I prep for a peer-to-peer with Geisinger Health Plan on NIVOLUMAB (Opdivo)?
Lead with the FDA-approved indication and the specific clinical criteria the policy lists. Have the patient's chart open, document number, and policy URL on screen. State your name and credentials, the policy number, the indication, and the documented failures of step-therapy alternatives. Keep notes — if the P2P reviewer overturns, get the decision in writing.
Related PA criteria
Generate the NIVOLUMAB (Opdivo) PA packet
Open ApprovalHelp — generate a NIVOLUMAB (Opdivo) prior-auth packet tailored to Geisinger Health Plan's criteria, with prescriber attestation and step-therapy documentation pre-filled.
Get started →Contact: hello@approvalhelp.com